Investigational Drug Information for Camostat
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug Camostat?
Camostat is an investigational drug.
There have been 24 clinical trials for Camostat.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2020.
The most common disease conditions in clinical trials are COVID-19, Coronavirus Infections, and Severe Acute Respiratory Syndrome. The leading clinical trial sponsors are Stanford University, Heinrich-Heine University, Duesseldorf, and Yale University.
There are one hundred and fifty-three US patents protecting this investigational drug and two international patents.
Summary for Camostat
| US Patents | 153 |
| International Patents | 2,592 |
| US Patent Applications | 1,127 |
| WIPO Patent Applications | 542 |
| Japanese Patent Applications | 230 |
| Clinical Trial Progress | Phase 2 (2020-05-01) |
| Vendors | 38 |
Recent Clinical Trials for Camostat
| Title | Sponsor | Phase |
|---|---|---|
| Camostat Mesylate for Protein-losing Enteropathy After Fontan Operation | Seoul National University Hospital | Phase 2 |
| The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications | Ono Pharmaceutical Co. Ltd | Phase 1/Phase 2 |
| The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications | Yale University | Phase 1/Phase 2 |
Clinical Trial Summary for Camostat
Top disease conditions for Camostat
Top clinical trial sponsors for Camostat
US Patents for Camostat
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Camostat | See Plans and Pricing | Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof | Signature Therapeutics, Inc. (San Carlos, CA) | See Plans and Pricing |
| Camostat | See Plans and Pricing | Substituted pyridines and method of use | AbbVie S.a.r.l. (Luzembourg, LU) Galapagos NV (Mechelen, BE) | See Plans and Pricing |
| Camostat | See Plans and Pricing | Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity | Parion Sciences, Inc. (Durham, NC) | See Plans and Pricing |
| Camostat | See Plans and Pricing | Crystallization method and bioavailability | GRUNENTHAL GMBH (DE) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Camostat
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Camostat | Australia | AU2010293028 | 2029-09-08 | See Plans and Pricing |
| Camostat | Brazil | BR112012005124 | 2029-09-08 | See Plans and Pricing |
| Camostat | Canada | CA2773340 | 2029-09-08 | See Plans and Pricing |
| Camostat | China | CN102695545 | 2029-09-08 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
